Filing summary
Entity discrepancy: The request identifies ANI Pharmaceuticals Inc., but the supplied Form 10-Q is for BioSante Pharmaceuticals, Inc. This summary reflects the filing provided, not ANI Pharmaceuticals.
Business context and reporting period
BioSante reported unaudited results for the quarter and six months ended June 30, 2012. The specialty pharmaceutical company focused on female sexual health and oncology. Its pipeline included LibiGel, GVAX cancer vaccines and The Pill-Plus; its licensed products included FDA-approved male testosterone gel and Elestrin. The filing gives effect to a one-for-six reverse stock split effective June 1, 2012.
Financial results and liquidity
| Metric | Three months ended June 30, 2012 | Six months ended June 30, 2012 |
|---|---|---|
| Revenue | $108,780 | $222,780 |
| Research and development expense | $5.40 million | $10.58 million |
| General and administrative expense | $1.95 million | $3.78 million |
| Net loss | $7.34 million | $17.61 million |
| Basic and diluted net loss per share | $0.36 | $0.89 |
- All reported revenue was royalty revenue from Elestrin sales through Jazz Pharmaceuticals; corresponding royalties payable to Antares offset that revenue in general and administrative expense. Revenue was not sufficient to make operating margins meaningful.
- Six-month operating cash use was $14.74 million, versus $24.36 million in the prior-year period. Investing cash use was $71,261; financing cash use was $658. Cash and equivalents declined by $14.81 million to $42.42 million.
- At June 30, total assets were $47.29 million, total liabilities $16.37 million and stockholders’ equity $30.92 million. The company had $11.78 million principal outstanding on 3.125% convertible notes due May 1, 2013; their carrying value was $10.48 million. After a July share exchange, principal outstanding was $8.28 million as of July 31.
- Accumulated deficit was $234.85 million. No credit facility was available.
Changes versus the prior comparable period
- Second-quarter revenue rose 34% from $81,003, while six-month revenue rose 61% from $138,003, but remained very small.
- R&D expense decreased 51% in the quarter and 59% for the six months, primarily because the two earlier LibiGel Phase III efficacy trials had concluded in late 2011.
- Net loss narrowed from $14.98 million to $7.34 million for the quarter and from $32.23 million to $17.61 million for the six months. Lower R&D spending was the main operating factor. The quarterly comparison also benefited from a $15,953 note fair-value adjustment versus a $1.75 million expense in 2011; the six-month 2012 period, however, included a $3.19 million note fair-value expense.
- Six-month G&A expense increased 6% to $3.78 million. The increase reflected personnel-related costs, professional fees and other administrative expenses.
Outlook, risks and unusual items
- Two prior pivotal LibiGel Phase III efficacy trials did not meet their co-primary or secondary endpoints; the filing attributed this to a greater-than-expected placebo response. In June 2012, BioSante announced plans for two new Phase III efficacy trials and continued its Phase III safety study. The company was developing protocols and seeking an FDA Special Protocol Assessment; it also disclosed a reasonable likelihood it might instead pursue a collaboration or other strategic alternative rather than launch the new efficacy trials.
- Management estimated the new efficacy trials would cost $30–$36 million combined over 18 months, and forecast R&D spending of approximately $1.7 million per month for the rest of 2012, assuming continuation of the safety study and no additional in-licensing. The company estimated June 30 cash would fund liquidity needs until approximately Q3 2013, absent additional licensing income or financing; management cautioned these estimates could prove incorrect.
- Management expected unblinded top-line safety-study data in Q4 2012. At the latest disclosed review, 3,656 subjects had enrolled, with over 5,800 subject-years of exposure; the independent monitoring committee recommended continuing the study without modifications.
- The remaining notes were scheduled to mature May 1, 2013. The company warned it might lack funds to repay them and had no assurance that financing would be available. Additional equity could dilute shareholders; debt, licensing or a sale or merger could carry other costs or consequences. The July 2012 note exchange reduced debt but issued 1,784,070 shares.
- A securities class action and shareholder derivative suits alleged misleading LibiGel disclosures and related governance claims. The cases were in early stages; BioSante said it could not estimate possible losses and believed the class action lacked merit.
- Other commitments included $510,436 remaining on a gel-packaging-machine purchase obligation. A June reverse split was undertaken primarily to help maintain Nasdaq Global Market listing.
- Management stated disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Confirm the issuer: the supplied filing is BioSante Pharmaceuticals, Inc., despite the ANI Pharmaceuticals request metadata.
- Track LibiGel trial protocol, FDA feedback/SPA status, funding, costs and safety-study results, particularly given the prior efficacy-trial failures.
- Assess cash burn and financing needs against the stated Q3 2013 cash-runway estimate and the May 2013 note maturity.
- Verify the effect of note exchanges and potential further equity issuance on debt repayment, dilution and share count.
- Monitor the status and potential financial impact of the securities and derivative litigation, and Teva’s timing, if any, for launching the approved male testosterone gel.